Windsor Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $788K | Buy |
3,129
+11
| +0.4% | +$2.37K | 0.2% | 66 |
|
|
2026
Q1 | $678K | Buy |
3,118
+319
| +11% | +$70.8K | 0.19% | 71 |
|
|
2025
Q4 | $639K | Buy |
2,799
+164
| +6% | +$37.4K | 0.18% | 75 |
|
|
2025
Q3 | $610K | Buy |
2,635
+7
| +0.3% | +$1.43K | 0.17% | 77 |
|
|
2025
Q2 | $488K | Buy |
2,628
+9
| +0.3% | +$1.67K | 0.14% | 87 |
|
|
2025
Q1 | $549K | Buy |
2,619
+49
| +2% | +$9.53K | 0.17% | 80 |
|
|
2024
Q4 | $457K | Buy |
2,570
+8
| +0.3% | +$1.47K | 0.14% | 89 |
|
|
2024
Q3 | $506K | Buy |
2,562
+128
| +5% | +$23.9K | 0.15% | 86 |
|
|
2024
Q2 | $417K | Buy |
2,434
+9
| +0.4% | +$1.49K | 0.13% | 87 |
|
|
2024
Q1 | $442K | Buy |
2,425
+116
| +5% | +$20K | 0.14% | 85 |
|
|
2023
Q4 | $358K | Buy |
2,309
+10
| +0.4% | +$1.46K | 0.12% | 89 |
|
|
2023
Q3 | $343K | Buy |
2,299
+8
| +0.3% | +$1.17K | 0.12% | 89 |
|
|
2023
Q2 | $309K | Buy |
2,291
+9
| +0.4% | +$1.32K | 0.1% | 90 |
|
|
2023
Q1 | $364K | Buy |
2,282
+8
| +0.4% | +$1.22K | 0.13% | 83 |
|
|
2022
Q4 | $368K | Buy |
2,274
+577
| +34% | +$88.5K | 0.13% | 82 |
|
|
2022
Q3 | $227K | Buy |
1,697
+8
| +0.5% | +$1.15K | 0.08% | 101 |
|
|
2022
Q2 | $258K | Buy |
1,689
+8
| +0.5% | +$1.22K | 0.09% | 102 |
|
|
2022
Q1 | $272K | Buy |
1,681
+8
| +0.5% | +$1.16K | 0.08% | 110 |
|
|
2021
Q4 | $226K | Buy |
+1,673
| New | +$198K | 0.07% | 111 |
|
|
2021
Q3 | – | Sell |
-2,117
| Closed | -$238K | – | 117 |
|
|
2021
Q2 | $238K | Buy |
2,117
+243
| +13% | +$27.4K | 0.08% | 108 |
|
|
2021
Q1 | $202K | Sell |
1,874
-490
| -21% | -$52.4K | 0.07% | 115 |
|
|
2020
Q4 | $253K | Buy |
2,364
+9
| +0.4% | +$865 | 0.09% | 104 |
|
|
2020
Q3 | $206K | Buy |
2,355
+9
| +0.4% | +$847 | 0.09% | 107 |
|
|
2020
Q2 | $230K | Buy |
+2,346
| New | +$207K | 0.1% | 104 |
|
|
2020
Q1 | – | Sell |
-2,377
| Closed | -$210K | – | 116 |
|
|
2019
Q4 | $210K | Buy |
+2,377
| New | +$197K | 0.09% | 114 |
|
|
2019
Q1 | – | Sell |
-2,471
| Closed | -$227K | – | 117 |
|
|
2018
Q4 | $227K | Sell |
2,471
-8,292
| -77% | -$729K | 0.12% | 106 |
|
|
2018
Q3 | $1.02M | Sell |
10,763
-359
| -3% | -$34K | 0.46% | 55 |
|
|
2018
Q2 | $1.03M | Buy |
11,122
+565
| +5% | +$55.2K | 0.48% | 54 |
|
|
2018
Q1 | $999K | Sell |
10,557
-1,492
| -12% | -$164K | 0.47% | 52 |
|
|
2017
Q4 | $1.17M | Sell |
12,049
-1,461
| -11% | -$138K | 0.54% | 43 |
|
|
2017
Q3 | $979K | Hold |
13,510
| – | – | 0.49% | 43 |
|
|
2017
Q2 | $979K | Buy |
13,510
+383
| +3% | +$25.7K | 0.49% | 43 |
|
|
2017
Q1 | $855K | Buy |
13,127
+8,822
| +205% | +$555K | 0.44% | 46 |
|
|
2016
Q4 | $269K | Buy |
4,305
+6
| +0.1% | +$366 | 0.15% | 99 |
|
|
2016
Q3 | $271K | Sell |
4,299
-8,645
| -67% | -$560K | 0.15% | 101 |
|
|
2016
Q2 | $801K | Buy |
12,944
+360
| +3% | +$21.9K | 0.47% | 48 |
|
|
2016
Q1 | $718K | Buy |
12,584
+3,310
| +36% | +$184K | 0.45% | 56 |
|
|
2015
Q4 | $549K | Buy |
9,274
+622
| +7% | +$35.8K | 0.34% | 62 |
|
|
2015
Q3 | $470K | Buy |
+8,652
| New | +$563K | 0.28% | 66 |
|
|
2014
Q1 | – | Sell |
-1,978
| Closed | -$104K | – | 89 |
|
|
2013
Q4 | $104K | Buy |
1,978
+5
| +0.3% | +$246 | 0.06% | 118 |
|
|
2013
Q3 | $88K | Sell |
1,973
-195
| -9% | -$8.64K | 0.05% | 125 |
|
|
2013
Q2 | $90K | Buy |
+2,168
| New | +$94.8K | 0.05% | 111 |
|
Other funds holding ABBV
ECSS
ATO
Windsor Capital Management's ABBV Position: Q2 2026 in Review
Windsor Capital Management increased its AbbVie (ABBV) stake by 0.35% in Q2 2026, buying an estimated $2.37K and bringing the position to 3,129 shares worth $788K. The position accounts for 0.2% of the portfolio, ranked #66.
Windsor Capital Management first reported a position in ABBV in Q2 2013 and has held it in 42 quarters since. The position peaked at $1.17M in Q4 2017. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Windsor Capital Management held 3,129 shares of AbbVie worth $788K as of Q2 2026.
- Windsor Capital Management bought 11 AbbVie shares in Q2 2026, an estimated $2.37K.
- AbbVie made up 0.2% of Windsor Capital Management's portfolio in Q2 2026, its #66 holding.
- Windsor Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 42 quarters since.
- Windsor Capital Management's AbbVie position peaked at $1.17M in Q4 2017.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Windsor Capital Management's 13F filing for Q2 2026, filed 8 Jul 2026.